SUBVENITE

Launch

lamotrigine

NDAORALSUSPENSION
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Organic Cation Transporter 2 Inhibitors

Pharmacologic Class:

Anti-epileptic Agent

Clinical Trials (5)

NCT07140913Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Started Oct 2025
424 enrolled
ManiaBipolar Disorder
NCT06729970Phase 1Completed

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Started Dec 2024
NCT04602221Phase 1Completed

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Started Dec 2020
40 enrolled
Healthy
NCT04156035N/ACompleted

Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine

Started Mar 2020
75 enrolled
Emotions
NCT02513654Phase 1Completed

Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects

Started Sep 2015
16 enrolled
Bipolar Disorder

Loss of Exclusivity

LOE Date
May 29, 2040
173 months away
Patent Expiry
May 29, 2040

Patent Records (2)

Patent #ExpiryTypeUse Code
11596634
May 29, 2040
U-4273
11612566
May 29, 2040
U-4273